Review scope
Included studies compared probiotics with placebo, no treatment, or another prophylactic treatment in adults (> 18 y of age) or children (≤ 18 y of age) who were receiving antibiotic therapy; and reported CDAD or C. difficile infection rates. Probiotics used as treatment for C. difficile infection were excluded. Outcomes were CDAD (diarrhea with C. difficile infection), C. difficile infection (positive stool cytotoxin or culture), adverse events, antibiotic-associated diarrhea (AAD), and hospital length of stay. Probiotic manufacturers were contacted. 31 RCTs (n = 4492) met the selection criteria: 27 used a placebo control, 3 no-treatment control, and 1 did not report the control intervention. 25 RCTs were done in adults, 3 in children, 2 in mixed populations, and 1 did not report patient age. 6 RCTs used allocation concealment, 22 used blinding for patients and clinicians, 22 used blinding for CDAD assessors, and 10 had adequate follow-up data for CDAD.
Review methods

MEDLINE
Main results
Probiotics reduced CDAD, AAD, and adverse events compared with control; groups did not differ for C. difficile infection or length of hospital stay (Table) .
Conclusion
Probiotics prevent C. difficile-associated diarrhea but not C. difficile infections in patients receiving antibiotics. 
Commentary
By the late 1970s, C. difficile had been identified as a major cause of AAD. Most cases of AAD resolved with discontinuation of antibiotics. More recalcitrant CDAD was usually successfully treated with oral metronidazole, although oral vancomycin was occasionally required, and some patients required colectomy or died from toxic megacolon. By the late 2000s, a new, more virulent strain of C. difficile (NAP1/BI/027) had spread around the world, causing more frequent, more severe, and more refractory disease. Minimizing use of antibiotics, hand washing, and environmental cleansing can reduce nosocomial transmission of CDAD (1); however, virulent CDAD continues to occur, including in nonhospitalized patients. Therefore, additional methods for reducing CDAD are needed.
Probiotics are live microorganisms taken for potential health benefits (2) . Trials have evaluated various probiotic organisms in experimental and clinical settings, in outpatients and inpatients, and have used different assays to diagnose C. difficile, making it difficult to select a regimen and be confident of a treatment effect.
In their meta-analysis, Goldenberg and colleagues addressed trial heterogeneity and missing data using accepted statistical methods, and they used appropriate clinical reasoning to assess potential risk for bias in a priori subgroups. They found moderate-quality evidence that probiotics reduce CDAD and adverse events but not C. difficile infection (C. difficile in stool or rectal swab in the absence of diarrhea). Although a recent multicenter, randomized, blinded, placebo-controlled trial of 2941 older inpatients found that a lactobacilli-bifidobacteria preparation did not reduce AAD, CDAD, or adverse events, both AAD and CDAD were much less frequent than expected (3). Therefore, even given this recent trial, the results of the meta-analysis by Goldenberg and colleagues encourage consideration of probiotics when prescribing antibiotics for patients at risk for CDAD. 
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